Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
about
Affinity and avidity in antibody-based tumor targetingMolecular Imaging of Pancreatic Cancer with Antibodies.Recombinant antibodies for cancer diagnosis and therapy.Nanobodies as novel agents for cancer therapy.Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.Exploiting the avian immunoglobulin system to simplify the generation of recombinant antibodies to allergenic proteins.Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds.Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Multiple-antigen immunization of chickens facilitates the generation of recombinant antibodies to autoantigens.Engineering of stable bispecific antibodies targeting IL-17A and IL-23.Development of homomultimers and heteromultimers of lung cancer-specific peptoids.Assessing combinatorial strategies to multimerize libraries of single-domain antibodies.Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agentsEnzymatic functionalization of a nanobody using protein insertion technology.A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.Monoclonal antibodies for brain tumour treatment.Hitting multiple targets with multimeric ligands.Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection.Recombinant approaches to IgG-like bispecific antibodies.T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.Tailoring antibodies for radionuclide delivery.Gene therapy vector design strategies for the treatment of cancer.Self-assembly of antibodies by chemical inductionProtein-based tumor molecular imaging probes.Enhanced targeting with heterobivalent ligandsSurface-active liposomes for targeted cancer therapy.Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody constructNANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS.A network medicine approach to human disease.Role of dimerization in the catalytic properties of the Escherichia coli disulfide isomerase DsbC.Antibody vectors for imaging.Research and development of next generation of antibody-based therapeuticsExploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.How to design multi-target drugs.Design and evaluation of radiolabeled tracers for tumor imaging.Radiolabeling strategies for tumor-targeting proteinaceous drugs.
P2860
Q24613552-F997157A-1DB6-4BFF-8224-2C268FD0B48FQ30393523-B67F22EF-C11A-4032-8C0C-FCDDA308FC22Q30771917-5D13EA0B-5C9D-44F4-85F8-A090B6AB02B7Q30778309-441CDE08-E8C0-4658-BBBA-BCDA1C112E00Q31016741-BC946A00-A084-40F7-B19A-81D758FEC988Q31100421-2DD53D92-3E7D-4CF5-B00F-5B811FCE6E54Q31155271-6CBC79FB-D002-4ADB-A0C0-822F9A8820C0Q33222202-98B702C8-5B66-4541-A0BA-D6C99783BE09Q33226563-1ACCCF97-1BC5-4EE9-9688-1841B5D9F3C7Q33234057-4AD5BFE5-D0CD-4B01-8336-BC3E1ECB4BE6Q33301860-647A201D-DFB5-4003-8DFA-720FE4998E4FQ33308916-A6DD2414-703A-4628-BAF4-F5C68CC14CA3Q33519833-62FD2F1B-312D-4336-9314-3B4417CF3B1AQ34105317-9AA5F8FA-1DCC-4A8E-90B9-793BC69A0DF4Q34668664-FF876CEC-3654-4FDD-AD4A-AC88A401E59AQ35082176-02E06D46-0CF7-4CE4-A786-0711EC2DF847Q35597176-8E79E4FE-EC38-4997-9DB4-B29719C6B9AAQ35871726-BE72E35A-30F5-4657-9EF4-2D1E675E0D10Q35873775-24158D12-FC41-455C-9A34-6777F898FDDDQ35976363-814031AC-C00A-4205-81EB-09B9440FBE10Q36130655-406FC89D-B1EB-4563-B2CB-255A7937FA9BQ36139512-01E59C7C-C24A-42A2-8E2C-05F4548AA52AQ36297606-E6FCA593-A1F2-44A2-BC7E-99692A21CCC0Q36349687-1AA3953F-212A-4942-9A3F-EEA694FFA258Q36429492-29419CC5-37AB-408E-A5B4-357A6CBB3D2CQ36611798-884F3444-AFC0-4685-BFAB-C3D2834DE7FAQ36742911-7DA96054-2CA7-4F97-80B3-1BC3D38E75E0Q36870878-EC317452-6F42-405E-B566-1E013F65B515Q36988355-9F54905E-ED5F-4392-BD4B-7528B1486695Q37102753-4A569BDA-4457-44D5-9ED8-BE7C6ECD0024Q37146338-0002FCF3-FBBE-48E1-AC42-8BE2633FCD7CQ37201160-D2F5C673-2E0A-4E85-931B-1D7BA3C8AABCQ37408792-E4697566-7C63-4BFA-90A3-C43218DEA1CAQ37433238-65D0A190-525E-4D7A-958C-C91F328B4835Q37720850-4CED812A-3F7D-42A3-8E50-A03101285FD5Q37778732-3FB48854-F5FD-4AFA-B9F7-1E1BF6D36523Q38075043-B1DD4BB2-89D9-46FA-BFFE-911A22E1F811Q38089151-C8B7246F-8B36-4D85-97B1-B559B2635CFBQ38137253-701EC2C6-4186-4610-B8F2-B1DF2053D7E2Q38189541-B85E35D6-F184-400F-8DB5-457C7BDC4FBA
P2860
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@ast
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@en
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@nl
type
label
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@ast
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@en
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@nl
prefLabel
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@ast
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@en
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@nl
P2093
P1476
Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
@en
P2093
Hoogenboom HR
Roovers RC
Todorovska A
P356
10.1016/S0022-1759(00)00342-2
P577
2001-02-01T00:00:00Z